Amicus Therapeutics (FOLD)
Healthcare · Biotechnology
1 member of Congress has disclosed 1 trade in Amicus Therapeutics (FOLD) since 2023: 0 buys and 1 sale. The most recent was disclosed on May 19, 2023.
- Trades disclosed
- 1
- Members trading
- 1
- Buys / sells
- 0 / 1
- Reported value
- $1K–$15K
Keep following the company.
Subscribers get new congressional filings and notable insider purchases for companies they follow. Coverage varies by company.
What else is happening at FOLD
All research →Company filings and public records connected to this stock, ordered by when they became public or were first observed.
FOLD: second_quarter 2026 lobbying report
Legislative and regulatory issues affecting SMID rare disease biotech companies. FDA approvals of rare diseases. Legislative and regulatory issues affecting SMID rare disease biotech companies.
Public: Jul 16, 2026, 3:36 PM EDTOriginal source ↗
Who traded FOLD
- Rep. Daniel S. Goldman (D-NY-10)0 buys · 1 sale01May 19, 2023
All trades
- May 19, 2023$1K–$15K
Rep. Daniel S. Goldman (D-NY-10)
$1K–$15K · Traded Apr 10, 2023 · disclosed May 19, 2023
From periodic transaction reports filed under the STOCK Act. Amounts are the ranges members report, and trades can be disclosed up to 45 days after they happen. Nothing here is investment advice.